You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


US green light for long-acting HIV regimen Cabenuva

The US Food and Drug Administration (FDA) has approved ViiV Healthcare and Janssen’s long-acting regimen for HIV-1 infection Cabenuva (cabotegravir, rilpivirine).